Composition and nutrient contents of the basal diet^a. by Miloš Skřivan (5122037)

Subjects:

PCoA plot analysis for dissimilarity. by Yu Sang Choi (22656230)

Subjects:

Composition of the gut microbiota at the genus level following the administration of MP. by Yu Sang Choi (22656230)

Subjects:

Performance characteristics of broilers. by Miloš Skřivan (5122037)

Subjects:

Disruption of hepatic metabolism in Lep KO mice. by Yu Sang Choi (22656230)

Subjects:

Digesta viscosity and pH in the ileum. by Miloš Skřivan (5122037)

Subjects:

Activity of xylanase in mixed feed and liver (mg saccharide/g sample/h), n = 12/treatment. by Miloš Skřivan (5122037)

Subjects:

Nutrient retention in broilers (g/kg/day). by Miloš Skřivan (5122037)

Subjects:

Composition of the gut microbiota at the phylum level following the administration of MP. by Yu Sang Choi (22656230)

Subjects:

Concentrations of fatty acids in the diet (mg/100 g). by Miloš Skřivan (5122037)

Subjects:

Comparison of (a) Chao index and (b) Shannon diversity index of the fecal microbiota in WT and Lep KO mice. by Yu Sang Choi (22656230)

Subjects:

Fatty acid composition (mg/100 g) of breast meat. by Miloš Skřivan (5122037)

Subjects:

Fat contents (g/kg) in breast meat and liver. by Miloš Skřivan (5122037)

Subjects:

Trends over 10 years (2011–2021) in clinical characteristics of children with severe acute malnutrition admitted at Moyo NRU. by Mphatso Nancy Chisala (20477275)

Trends over 10 years in children with severe acute malnutrition admitted at Moyo NRU. by Mphatso Nancy Chisala (20477275)

No significant differences in the numbers of eggs between Mst1^+/+ and Mst1^ΔM/ΔM mice. by Jianyang Li (461703)

Blood Pressure and LDL-C During Follow-up. by Karl Ingard (22582091)

Subjects:

Baseline Characteristics of Included Patients. by Karl Ingard (22582091)

Subjects:

Discovery of an Orally Active PDE1 Inhibitor for Disease-Modifying Treatment of Postmenopausal Osteoporosis via Dual Anabolic-Antiresorptive Mechanisms by Farman M. Abbasi (22318766)

“…Postmenopausal osteoporosis (PMO) is characterized by an imbalance in bone remodeling with increased osteoclast and decreased osteoblast activity, leading to bone loss and higher fracture risk. …”

Discovery of an Orally Active PDE1 Inhibitor for Disease-Modifying Treatment of Postmenopausal Osteoporosis via Dual Anabolic-Antiresorptive Mechanisms by Farman M. Abbasi (22318766)

“…Postmenopausal osteoporosis (PMO) is characterized by an imbalance in bone remodeling with increased osteoclast and decreased osteoblast activity, leading to bone loss and higher fracture risk. …”